Cargando…

Secretory units of islets in transplantation index is a useful clinical marker to evaluate the efficacy of sitagliptin in treatment of type 2 diabetes mellitus

We carried out a retrospective analysis of 40 Japanese patients with type 2 diabetes mellitus who received sitagliptin. Glycated hemoglobin (HbA(1c)) and fasting plasma glucose were significantly decreased from 7.53 ± 0.65% and 155.2 ± 29.4 mg/dL at baseline to 6.80 ± 0.60% (P < 0.01) and 131.2 ±...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kubota, Akira, Matsuba, Ikuro, Saito, Tatsuhiko, Nabe, Koichiro, Seino, Yutaka
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell Publishing Ltd 2011
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4019306/ https://www.ncbi.nlm.nih.gov/pubmed/24843517 http://dx.doi.org/10.1111/j.2040-1124.2011.00109.x

Ejemplares similares

Factors influencing the durability of the glucose‐lowering effect of sitagliptin combined with a sulfonylurea
por: Kubota, Akira, et al.
Publicado: (2014)

Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer
por: Kanamori, Akira, et al.
Publicado: (2013)

Pleiotropic Effects of Sitagliptin in the Treatment of Type 2 Diabetes Mellitus Patients
por: Kubota, Akira, et al.
Publicado: (2012)

Factor Analysis of Changes in Hemoglobin A1c After 12 Months of Sitagliptin Therapy in Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2016)

A Study of Seasonal Variation in the Effect of Add-On Sitagliptin on Blood Glucose Control in Insulin-Treated Patients With Type 2 Diabetes
por: Takai, Masahiko, et al.
Publicado: (2020)

Secretory units of islets in transplantation index is a useful predictor of insulin requirement in Japanese type 2 diabetic patients
por: Iwata, Minoru, et al.
Publicado: (2013)

Primary Care-Based Investigation of the Effect of Sitagliptin on Blood Pressure in Hypertensive Patients With Type 2 Diabetes
por: Yuasa, Shouhei, et al.
Publicado: (2017)

Efficacy and safety of sitagliptin monotherapy and combination therapy in Japanese type 2 diabetes patients
por: Kubota, Akira, et al.
Publicado: (2012)

Efficacy and safety of sitagliptin as compared with glimepiride in Japanese patients with type 2 diabetes mellitus aged ≥ 60 years (START‐J trial)
por: Terauchi, Yasuo, et al.
Publicado: (2017)

Islet Transplantation in Type I Diabetes Mellitus
por: Jamiolkowski, Ryan M., et al.
Publicado: (2012)

Animal Models of Diabetes Mellitus for Islet Transplantation
por: Sakata, Naoaki, et al.
Publicado: (2012)

Anti-atherosclerotic effects of sitagliptin in patients with type 2 diabetes mellitus
por: Omoto, Seitaro, et al.
Publicado: (2015)

Endocrine Secretory Reserve and Proinsulin Processing in Recipients of Islet of Langerhans Versus Whole Pancreas Transplants
por: Elkhafif, Nabeel M., et al.
Publicado: (2013)

Incretin concept revised: The origin of the insulinotropic function of glucagon‐like peptide‐1 – the gut, the islets or both?
por: Yabe, Daisuke, et al.
Publicado: (2017)

Effect of Exenatide, Sitagliptin, or Glimepiride on β-Cell Secretory Capacity in Early Type 2 Diabetes
por: Gudipaty, Lalitha, et al.
Publicado: (2014)

Factors Predicting Therapeutic Efficacy of Combination Treatment With Sitagliptin and Insulin in Type 2 Diabetic Patients: The ASSIST-K Study
por: Ishikawa, Masashi, et al.
Publicado: (2015)

Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study
por: Takai, Masahiko, et al.
Publicado: (2019)

Improvement in β-Cell Secretory Capacity After Human Islet Transplantation According to the CIT07 Protocol
por: Rickels, Michael R., et al.
Publicado: (2013)

Efficacy and Safety of Alogliptin in Elderly Patients With Type 2 Diabetes Mellitus
por: Takeda, Hiroshi, et al.
Publicado: (2019)

Two-year assessment of the efficacy and safety of sitagliptin in elderly patients with type 2 diabetes: Post hoc analysis of the ASSET-K study
por: Umezawa, Shinichi, et al.
Publicado: (2015)

Sitagliptin as combination therapy in the treatment of type 2 diabetes mellitus
por: Miller, Shannon A, et al.
Publicado: (2009)

Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus
por: Mori, Hiroko, et al.
Publicado: (2013)

Islet Function and Insulin Sensitivity in Latent Autoimmune Diabetes in Adults Taking Sitagliptin: A Randomized Trial
por: Yang, Lin, et al.
Publicado: (2021)

Efficacy and safety of ipragliflozin in Japanese patients with type 2 diabetes and inadequate glycaemic control on sitagliptin
por: Kaku, Kohei, et al.
Publicado: (2021)

Insulin secretory capacity and insulin sensitivity in impaired fasting glucose in Japanese
por: Mitsui, Rie, et al.
Publicado: (2012)

Pancreas transplant in type 1 diabetes mellitus: the emerging role of islet cell transplant
por: Kochar, Inderpal Singh, et al.
Publicado: (2021)

ISOLATION AND PROPERTIES OF SECRETORY GRANULES FROM RAT ISLETS OF LANGERHANS : I. Isolation of a Secretory Granule Fraction
por: Howell, S. L., et al.
Publicado: (1969)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

Nonhuman Primate Models of Type 1 Diabetes Mellitus for Islet Transplantation
por: Zhu, Haitao, et al.
Publicado: (2014)

Altered Islet Morphology but Normal Islet Secretory Function In Vitro in a Mouse Model with Microvascular Alterations in the Pancreas
por: Kostromina, Elena, et al.
Publicado: (2013)

Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes
por: Seino, Yutaka, et al.
Publicado: (2017)

Characterization of proinsulin- and proglucagon-converting activities in isolated islet secretory granules
Publicado: (1981)

Fasting Insulin Levels and Metabolic Risk Factors in Type 2 Diabetic Patients at the First Visit in Japan: A 10-year, nationwide, observational study (JDDM 28)
por: Matsuba, Ikuro, et al.
Publicado: (2012)

Sitagliptin and Roux‐en‐Y gastric bypass modulate insulin secretion via regulation of intra‐islet PYY
por: Guida, Claudia, et al.
Publicado: (2017)

Effect of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus
por: Shigematsu, Erina, et al.
Publicado: (2014)

Effects of Sitagliptin on Insulin and Glucagon Levels in Type 2 Diabetes Mellitus
por: Kim, Ji Hyun
Publicado: (2015)

Cardiovascular risk of sitagliptin in treating patients with type 2 diabetes mellitus
por: Zeng, De-kang, et al.
Publicado: (2019)

Papulonodular Lesions in a Patient of Diabetes Mellitus Receiving Sitagliptin and Metformin
por: Agrawal, Prabhat, et al.
Publicado: (2021)

Association between osteocalcin, a pivotal marker of bone metabolism, and secretory function of islet beta cells and alpha cells in Chinese patients with type 2 diabetes mellitus: an observational study
por: Lei, Haiyan, et al.
Publicado: (2022)

Evaluating the Prognostic Value of Islet Autoantibody Monitoring in Islet Transplant Recipients with Long-Standing Type 1 Diabetes Mellitus
por: Anteby, Roi, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_64bp43hg2uj9vls108ftvmqmia